# Taliglucerase Alfa (Elelyso)

Source: https://ourhealthnetwork.com/drugs/taliglucerase-alfa
Data: FDA Orange Book and OpenFDA, refreshed periodically

## What is Taliglucerase Alfa?

Taliglucerase Alfa (brand name: Elelyso) is a hydrolytic lysosomal glucocerebroside-specific enzyme.

## Brand names

Elelyso

## Indications

ELELYSO is indicated for the treatment of patients 4 years of age and older with a confirmed diagnosis of Type 1 Gaucher disease. ELELYSO is a hydrolytic lysosomal glucocerebroside-specific enzyme indicated for the treatment of patients 4 years and older with a confirmed diagnosis of Type 1 Gaucher disease ( 1 ).

## Conditions treated

- [Gaucher Disease](https://ourhealthnetwork.com/conditions/gaucher-disease)

## Mechanism of action

Gaucher disease is an autosomal recessive disorder caused by mutations in the human glucocerebrosidase gene, which results in a reduced activity of the lysosomal enzyme glucocerebrosidase. Glucocerebrosidase catalyzes the conversion of the sphingolipid glucocerebroside into glucose and ceramide.

## Drug classification

- Established Pharmacologic Class: Hydrolytic Lysosomal Glucocerebroside-specific Enzyme [EPC]
- Route of administration: INTRAVENOUS

## Common side effects

abdominal pain, arthralgia, dizziness, fatigue, flushing, nausea, pruritus, urticaria ( 6

## Sources and disclaimers

- FDA Orange Book and OpenFDA dataset
- This information is for educational purposes only and does not constitute medical advice. Always consult a healthcare professional before starting, stopping, or changing any medication.

## Related

- [All drugs](https://ourhealthnetwork.com/drugs)
- [Find specialists who prescribe this drug](https://ourhealthnetwork.com/find-doctors)
- [Methodology](https://ourhealthnetwork.com/methodology)